DUBLIN, Aug. 07, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/bhw75w/investigation) has announced the addition of the "Investigation Report on China's Lamivudine Market, 2010-2019" report to their offering.
According to the report issued by the Joint United Nations Programme on HIV and AIDS in 2014, by the end of 2013, patients with human immune deficiency virus/acquired immune deficiency syndrome (HIV/ AIDS) had amounted to 35 million and the number of new cases of HIV/AIDS had been 6,000 a day on average. And by the end of 2011, patients with HIV/AIDS in China was estimated to be 0.78 million, the number of new cases of HIV/AIDS was 48,000 and people dying of diseases related with AIDS reached 28,000.
Lamivudine, an important drug for hepatitis B Virus (HBV) and AIDS, is one of the products regulated by the Chinese government to be provided to patients with AIDS (patients with hepatitis B not included) for free. As an antiviral nucleotide analog, lamivudine can competitively inhibit the synthesis and elongation of the viral DNA chain. First used by some countries in Europe and North America for the treatment of AIDS in the early 1990s, lamivudine was approved by the FDA to be used for the treatment of hepatitis B in 1998 after some medical experts discovered its inhibiting effect on HBV DNA in the middle 1990's. Lamivudine was approved by the CFDA mainly as an hepatitis B drug and began its sales in China in 1999.
Lamivudine developed fast after entering China with sales value reaching up to CNY 307 million in 2012 despite its gradual drop since 2013. GlaxoSmithKline Pharmaceuticals (Suzhou) Limited, Beijing Wansheng Pharmaceutical Co., Ltd, Burroughs Wellcome & Company (UK) and Fujian Cosunter Pharmaceutical Co., Ltd occupy the majority of the Chinese market, among of which GlaxoSmithKline Pharmaceuticals (Suzhou) Limited had the largest market share of about 72% for sales value in 2014.
With the large amounts of patients with hepatitis B and AIDS in China, the market size of lamivudine is expected to have growth potential.
Key Topics Covered:
1 Related Concepts of Lamivudine
2 Market Profile of Lamivudine in China
3 Survey on Sales Status of Lamivudine in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Lamivudine in China, 2010-2014
5 Survey on Dosage Forms of Lamivudine in China, 2010-2014
6 Reference Price of Lamivudine in Chinese Hospitals in 2014
7 Major Manufacturers of Lamivudine in Chinese Market, 2010-2014
8 Market Outlook of Lamivudine in China, 2015-2019
- Anhui Biochem United Pharmaceutical Co., Ltd
- Fujian Cosunter Pharmaceutical Co., Ltd
- Beijing Wansheng Pharmaceutical Co., Ltd
- GlaxoSmithKline Pharmaceuticals (Suzhou) Limited
- Hunan Qianjin Xiangjiang Pharmaceutical Industry Co., Ltd
For more information visit http://www.researchandmarkets.com/research/bhw75w/investigation
Media Contact: Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets